货号: abs811077
货号-规格 | 货期 | 价格 | 数量 |
abs811077-5mg | 4周 | ¥4624.00 | - + |
abs811077-10mg | 4周 | ¥8346.00 | - + |

产品描述 | ||
描述 | Bay 65-1942 is an ATP-competitive inhibitor that selectively targets IKKβ kinase activity. | |
纯度 | >98% | |
储存/保存方法 | store at -20℃ for one year(Powder);
in DMSO or others solvent store at 2-4℃ for two weeks, at -20℃ for six months. | |
基本信息 | ||
可溶性/溶解性 | 10 mM in DMSO | |
生物活性 | ||
靶点 | IKK | |
In vitro(体外研究) | Delivery of Bay 65-1942 prior to ischemia significantly decreases left ventricular infarct size compared with animals receiving vehicle. Compared with sham animals, animals receiving vehicle have a significant increase in the infarct-to-area at risk (AAR) ratio (70.7±3.4 vs. 5.8±3.4%, P. | |
In vivo(体内研究) | Inhibitors of MEK (AZD6244) and IKK (BAY 65-1942) are used at their IC50 concentrations, as determined by a 48 hour MTS assay, which achieve sufficient inhibition of kinase activity. MYL-R cells are treated for 24 hours with AZD6244 (5 µM), BAY 65-1942 (10 µM), or a combination of these inhibitors at the same concentrations. AZD6244 and BAY 65-1942 demonstrate synergistic inhibition of cell viability at the dose combination (5 µM AZD6244+10 µM BAY 65-1942), which correlates with IC75 (CI = 0.48±0.01). Synergism is also indicated at the IC50 (CI = 0.56±0.09) and IC90 (CI = 0.46±0.02) dose combinations reported by the software (CI values are the mean of three independent experiments, ± standard deviation). AZD6244 and BAY 65-1942 treatment induces 2- and 1.3-fold caspase 3/7 activation, respectively, compared to the DMSO-treated cells. Treatment with a combination of AZD6244 plus BAY 65-1942 leads to a 3.2-fold increase in caspase 3/7 activity. | |
温馨提示:本产品仅作科研实验使用,不支持临床等研究 |
- 提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要提问”按钮填写您的疑问。
提交不成功?请联系info@absin.cn。
促销资讯 更多
订购信息
您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。